In a real-world US registry of patients undergoing TAVR, 1-year mortality was 23.7% and the stroke rate was 4.1%, providing important prognostic information for routine clinical practice.
No takes yet. Share an insight, caveat, or question.
These rates inform TAVR risk discussions in practice; leaves open whether targeted interventions can improve outcomes in high-risk subgroups.
Holmes et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: